The Department of Pharmacology at the University of Cambridge, in partnership with AstraZeneca, offers a funded PhD studentship focused on proteasome-targeting tools and novel approaches for Targeted Protein Degradation (TPD).
You will join Dr Catherine Lindon's lab, work independently with a supervisory team, and contribute to discovering Midnolin binders and engineering degrader tools for oncology targets within a four-year program.
#J-18808-Ljbffr
PhD in Targeted Protein Degradation Tools - Cambridge employer: University of Cambridge
The University of Cambridge offers a dynamic and collaborative work environment, particularly within the Department of Oncology, where you will play a pivotal role in advancing cancer research. With a strong emphasis on employee growth, you will have access to professional development opportunities and the chance to work alongside leading experts in the field. The university's commitment to innovation and excellence ensures that your contributions will have a meaningful impact on clinical care and research outcomes.
